Radiosensitivity of prostate cancer cells is enhanced by EGFR inhibitor C225

Urologic Oncology: Seminars and Original Investigations

Volumn 28, Issue 1, 2010, Pages 59-66

  Liu, Feng ^a   Wang, Jun Jie ^a   You, Zhen Yu ^a   Zhang, Ying Dong ^a   Zhao, Yong ^b  

^a PEKING UNIVERSITY THIRD HOSPITAL   (China)

^b INSTITUTE OF ZOOLOGY   (China)

Author keywords

Apoptosis; Cell proliferation; EGFR inhibitor; Prostate cancer cells

Indexed keywords

CETUXIMAB; CYCLIN D1; CYCLIN DEPENDENT KINASE 2; CYCLIN DEPENDENT KINASE 4; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE P38; SURVIVIN;

APOPTOSIS; ARTICLE; CELL CYCLE ARREST; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CELL CYCLE S PHASE; CELL PROLIFERATION; CELL SURVIVAL; COBALT THERAPY; CONTROLLED STUDY; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; HUMAN; HUMAN CELL; MALE; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; RADIATION DOSE; RADIOSENSITIZATION;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; HUMANS; MALE; PROSTATIC NEOPLASMS; RADIATION TOLERANCE; RECEPTOR, EPIDERMAL GROWTH FACTOR; TUMOR CELLS, CULTURED;

EID: 72549101791     PISSN: 10781439     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.urolonc.2008.07.001     Document Type: Article

References (43)

1. Formento P., Hannoun-Levi J.M., Gerard F., et al. Gefitinib-trastuzumab combination on hormone-refractory prostate cancer xenograft. Eur J Cancer 41 (2005) 1467-1473
2. Kim J.H., Xu C.J., Keum Y.S., et al. Inhibition of EGFR signaling in human prostate cancer PC-3 cells by combination treatment with β-phenylethyl isothiocyanate and curcumin. Carcinogenesis 27 (2006) 475-482
3. Mimeault M., Johansson S.L., Vankatraman G., et al. Combined targeting of epidermal growth factor receptor and hedgehog signaling by gefitinib and cyclopamine cooperatively improves the cytotoxic effects of docetaxel on metastatic prostate cancer cells. Mol Cancer Ther 6 (2007) 967-978
4. Shuch B., Mikhail M., Satagopan J., et al. Racial disparity of epidermal growth factor receptor expression in prostate cancer. J Clin Oncol 22 (2004) 4725-4729
5. Bektas M., Payne S.G., Liu H., et al. A novel acylglycerol kinase that produces lysophosphatidic acid modulates cross talk with EGFR in prostate cancer cells. J Cell Biol 169 (2005) 801-811
6. Liu Y.Q., Poon R.T., Shao W., et al. Blockage of epidermal growth factor receptor by quinazoline tyrosine kinase inhibitors suppresses growth of human hepatocellular carcinoma. Cancer Lett 248 (2007) 32-40
7. Dittmann K., Mayer C., Fehrenbacher B., et al. Radiation-induced epidermal growth factor receptor nuclear import is linked to activation of DNA-dependent protein kinase. J Biol Chem 280 (2005) 31182-31189
8. Kao J., Turian J., Meyers A., et al. Sparing of the penile bulb and proximal penile structures with intensity-modulated radiation therapy for prostate cancer. Br J Radiol 77 (2004) 129-136
9. Namiki S., Ishidoya S., Tochigi T., et al. Health-related quality of life after intensity modulated radiation therapy for localized prostate cancer: Comparison with conventional and conformal radiotherapy. Jpn J Clin Oncol 36 (2006) 224-230
10. Wilt T.J., MacDonald R., Rutks I., et al. Systematic review: Comparative effectiveness and harms of treatments for clinically localized prostate cancer. Ann Intern Med 148 (2008) 435-448
11. Pan X., and Lee R.J. Construction of anti-EGFR immunoliposomes via folate-folate binding protein affinity. Int J Pharm 336 (2007) 276-283
12. Italiano A., Vandenbos B.F., Otto J., et al. Comparison of the epidermal growth factor receptor gene and protein in primary non-small-cell lung cancer and metastatic sites: Implications for treatment with EGFR-inhibitors. Ann Onc 17 (2006) 981-985
13. Harari P.M., and Huang S.M. Head and neck cancer as a clinical model for molecular targeting of therapy: Combining EGFR blockade with radiation. Int J Radiat Oncol Biol Phys 49 (2001) 427-433
14. Sok J.C., Coppelli F.M., Thomas S.M., et al. Mutant epidermal growth factor receptor (EGFRvIII) contributes to head and neck cancer growth and resistance to EGFR targeting. Clin Cancer Res 12 (2006) 5064-5073
15. Zhou Y.F., Li S., Hu Y., et al. Blockade of EGFR and ErbB2 by the novel dual EGFR and ErbB2 tyrosine kinase inhibitor GW572016 sensitizes human colon carcinoma GEO cells to apoptosis. Clinic Cancer Res 12 (2006) 3723-3729
16. Raben D., Helfrich B., Chan D.C., et al. The effects of cetuximab alone and in combination with radiation and/or chemotherapy in lung cancer. Clin Cancer Res 11 (2005) 795-805
17. Guerin O., Formento P., Nigro C.L., et al. Supra-additive antitumor effect of sunitinib malate (SU11248, Sutent) combined with docetaxel A new therapeutic perspective in hormone refractory prostate cancer. J Cancer Res Clin Oncol 134 (2008) 51-57
18. Supiot S., Hill R.P., and Bristow R.G. Nutlin-3 radiosensitizes hypoxic prostate cancer cells independent of p53. Mol Cancer Ther 7 (2008) 993-999
19. Winter R.N., Rhee J.G., and Kyprianou N. Caspase-1 enhances the apoptotic response of prostate cancer cells to ionizing radiation. Anticancer Res 24 (2004) 1377-1386
20. Warren G., Grimes K., Xu Y., et al. Selectively enhanced radiation sensitivity in prostate cancer cells associated with proteasome inhibition. Oncol Rep 15 (2006) 1287-1291
21. Ukomadu C., and Dutta A. p21-Dependent inhibition of colon cancer cell growth by mevastatin is independent of inhibition of G1 cyclin-dependent kinases. J Biol Chem 278 (2003) 43586-43594
22. Singh R.P., Agrawal P., Yim D., et al. Acacetin inhibits cell growth and cell cycle progression, and induces apoptosis in human prostate cancer cells: Structure-activity relationship with linarin and linarin acetate. Carcinogenesis 26 (2005) 845-854
23. Paduano F., Villa R., Pennati M., et al. Silencing of survivin gene by small interfering RNAs produces supra-additive growth suppression in combination with 17-allylamino-17-demethoxygeldanamycin in human prostate cancer cells. Mol Cancer Ther 5 (2006) 179-186
24. Fornaro M., Plescia J., Cheang S., et al. Fibronectin protects prostate cancer cells from tumor necrosis factor-induced apoptosis via the AKT/Survivin pathway. J Biol Chem 278 (2003) 50402-50411
25. Quann E.J., Khwaja F., and Djakiew D. The p38 MAPK pathway mediates Aryl propionic acid-induced messenger RNA stability of p75NTR in prostate cancer cells. Cancer Res 67 (2007) 11402-11410
26. Ghosh A.K., Steele R., and Ray R.B. c-myc Promoter-binding protein 1 (MBP-1) regulates prostate cancer cell growth by inhibiting MAPK pathway. J Biol Chem 280 (2005) 14325-14330
27. Yeh A.H., Jeffery P.L., Russell P., et al. Ghrelin and a novel preproghrelin isoform are highly expressed in prostate cancer and ghrelin activates mitogen-activated protein kinase in prostate cancer. Clin Cancer Res 11 (2005) 8295-8303
28. Papatsoris A.G., Karamouzis M.V., and Papavassiliou A.G. The power and promise of "rewiring" the mitogen-activated protein kinase network in prostate cancer therapeutics. Mol Cancer Ther 6 (2007) 811-819
29. Huang M., Li J., Armstrong A., et al. Modulation of radiation response and tumor-induced angiogenesis after epidermal growth factor receptor inhibition by ZD1839 (Iressa). Cancer Res 62 (2002) 4300-4306
30. Midathada MV, Kaushal RD, Kohli M. Role of androgen deprivation in EGFR and Her-2/neu gene expression patterns in prostate cancer. Proceedings of the ASCO Meeting, New Orleans, LA, June 2004; [Abstract].
31. Marciniak D.J., Rishi A.K., Sarkar F.H., et al. Epidermal growth factor receptor-related peptide inhibits growth of PC-3 prostate cancer cells. Mol Cancer Ther 3 (2004) 1615-1621
32. Collis S.J., Schwaninger J.M., Ntambi A.J., et al. Evasion of early cellular response mechanisms following low level radiation-induced DNA damage. J Biol Chem 279 (2004) 49624-49632
33. 60Co γ rays. Int J Radiat Oncol Biol Phys 63 (2005) 224-229
34. Armpilia C.I., Dale R.G., Coles I.P., et al. The determination of radiobiologically optimized half-lives for radionuclides used in permanent brachytherapy implants. Int J Radiat Oncol Biol Phys 55 (2003) 378-385
35. Albert A., Marian A., Marieke R., et al. Cell cycle perturbations and radiosensitization effects in a human prostate cancer cell line. Cancer Res Clin Oncol 129 (2003) 175-182
36. Pawlik T.M., and Keyomarsi K. Role of cell cycle in mediating sensitivity to radiotherapy. Int J Radiat Oncol Biol Phys 59 (2004) 928-942
37. Rithedech K.N., Tungjai M., Arbab E., et al. Induction of radio-resistance by low dose X-irradiation. Cancer Res 126 (2006) 833-840
38. Klausen P., Bjerregaard M.D., Borregaard N., et al. End-stage differentiation of neutrophil granulocytes in vivo is accompanied by up-regulation of p27kip1 and down-regulation of CDK2, CDK4, and CDK6. J Leukoc Biol 75 (2004) 569-578
39. Pisarev V., Yu B., Salup R., et al. Full-length dominant-negative survivin for cancer immunotherapy. Clin Cancer Res 9 (2003) 6523-6533
40. Chun J.Y., Hu Y., Pinder E., et al. Selenium inhibition of survivin expression by preventing Sp1 binding to its promoter. Mol Cancer Ther 6 (2007) 2572-2580
41. Kari C., Chan T.O., Quadros M.R., et al. Targeting the epidermal growth factor receptor in cancer: Apoptosis takes center stage. Cancer Res 63 (2003) 1-5
42. Oleg T., and Graham C. Bax activation and translocation to mitochondria mediate EGF-induced programmed cell death. J Cell Sci 118 (2005) 5681-5690
43. Wang Q., and Greene M.I. EGFR enhances Survivin expression through the phosphoinositide 3 (PI-3) kinase signaling pathway. Exp Mol Pathol 79 (2005) 100-107